Literature DB >> 8580943

Electrovaporization of the prostate: new technique for treatment of symptomatic benign hyperplasia.

S C Stewart1, D Benjamin, H Ruckle, P Lui, R Hadley.   

Abstract

This pilot study evaluated the efficacy of a newly configured roller electrode (Circon/ACMI Vaportrode) in the treatment of symptomatic benign prostatic hyperplasia. The electrode is used with a cutting current and an otherwise-standard (ACMI) resectoscope. Thirty-four patients with significant symptoms of bladder outlet obstruction were treated and evaluated. Among them, 20 were in urinary retention, and 14 had moderate to severely symptomatic bladder outlet obstruction. Thirty-three patients are voiding and available for follow-up. The other patient has not returned. All available patients have shown both subjective and objective voiding improvement. In the evaluable patients, the AUA Symptom Index decreased from a mean of 26 to 12. The mean postoperative peak urinary flow rate was 13 mL/sec. Complications occurred in three patients (post-operative bleeding in one, urinary retention in two). Electrovaporization allowed definitive treatment of bladder outlet obstruction with subjectively better visibility than transurethral resection (TURP). The potential for fluid and electrolyte shifts and resulting complications appears to be less than with TURP. Further study of this technique appears warranted.

Entities:  

Mesh:

Year:  1995        PMID: 8580943     DOI: 10.1089/end.1995.9.413

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  2 in total

Review 1.  Transurethral vaporization of the prostate: current techniques.

Authors:  M A Cabelin; A E Te; S A Kaplan
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

2.  Does the Intensity of Cutting Power Affect Postoperative Symptoms During Transurethral Resection with a Monopolar System?

Authors:  Mustafa Kirac; Çagrı Guneri; Nuri Deniz; Hasan Biri
Journal:  Indian J Surg       Date:  2013-06-19       Impact factor: 0.656

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.